1st Edition

Omics Technologies in Cancer Biomarker Discovery

By Xuewu Zhang Copyright 2011
150 Pages 18 B/W Illustrations
by CRC Press

150 Pages
by CRC Press

The early detection of human cancer is still one of the great challenges in the battle against this disease. Single biomarkers are not likely to provide sufficient diagnostic power and multibiomarker assays should be developed in order to reach high diagnostic accuracy for cancer screening at the population level. Omics technologies are emerging new biomarker discovery tools and have a high... Read more
1. Genomics in Cancer Biomarker D iscovery2. Transcriptomics in Cancer Biomarker Discovery 3. Proteomics in Cancer Biomarker Discovery 4. Metabonomics in Cancer Biomarker Discovery 5. Peptidomics in Cancer Biomarker Discovery6. Phosphoproteomics in Cancer Biomarker Discovery 7. Usefulness of Immunomics in Cancer Biomarker Discovery 8. Glycoproteomics in Cancer Biomarker Discovery 9. Lipidomics in Cancer Biomarker Discovery 10. Bioinformatics in Cancer Biomarker Discovery 11. Integrative Omics Technologies in Cancer Biomarker Discovery

Biography

Xuewu Zhang received his BSc in Mathematics in 1983 at Hunan Normal University, China. He got his MSc degree in Ecology in 1990 and PhD degree in Entomology in 1993, both from Zhongshan University, China. Then he worked at the Food Engineering Research Center of State Education Ministry, Zhongshan University, China. After May of 1998, he was invited to do postdoctoral research at several universities, including The University of Hong Kong, University of British Columbia (Canada), University of Manitoba (Canada) and University of California at Los Angeles (USA). In January of 2003, under the scheme “Admission of Talents, he returned to The University of Hong Kong as a Research Assistant Professor. In August o f2005, he joined the South China University of Technology as a Professor. Currently his main research interest focuses on target identification of biopharmaceuticals and nutraceuticals with omics technologies.